Active surveillance for metastatic or recurrent renal cell carcinoma

Purpose Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms. Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients was retrospectively evaluated. Methods mRCC p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2014-08, Vol.140 (8), p.1421-1428
Main Authors: Park, Inkeun, Lee, Jae-Lyun, Ahn, Jin-Hee, Lee, Dae-Ho, Lee, Kyoo-Hyung, Jeong, In Gab, Song, Cheryn, Hong, Bumsik, Hong, Jun Hyuk, Ahn, Hanjong
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cancer Research
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - secondary
Carcinoma, Renal Cell - therapy
Disease Progression
Female
Hematology
Humans
Internal Medicine
Kaplan-Meier Estimate
Kidney cancer
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Kidney Neoplasms - therapy
Male
Medicine
Medicine & Public Health
Metastasis
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local - prevention & control
Oncology
Original Article – Clinical Oncology
Proportional Hazards Models
Retrospective Studies
Surveillance
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Metastatic renal cell carcinoma (mRCC) sometimes presents with an indolent course without any significant symptoms. Here, the potential impact of active surveillance (AS) on clinical outcomes in asymptomatic or minimally symptomatic mRCC patients was retrospectively evaluated. Methods mRCC patients who were followed up with deferred treatment for the purpose of AS between 2000 and 2012 were enrolled. Patient and disease characteristics, outcomes of AS and subsequent therapies, and predictive factors for rapid disease progression were analyzed. The primary endpoint was time-to-progression (TTP). Results First-line systemic therapy was deliberately deferred in 58 patients. During AS, the best overall responses were stable disease for 48 patients (83 %) and progressive disease (PD) for 10 patients (17 %), and 47 patients ultimately experienced disease progression at the time of data cutoff. With a median follow-up of 31.4 months, the median TTP was 12.4 months (95 % confidence interval 8.4–16.5) and median overall survival was not reached. After univariate and multivariate analyses for TTP, Karnofsky performance status
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-014-1680-9